Список проголосовавших за комментарий " Gapping up/down: RH +17%, VRNT +8% and UNF +2% after earnings, EXAR +22% after M&A news, FTNT +2% and MS +1% after upgrades: PLAY -3% and SONC -1% after earnings, FFIV -3% after dg<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>RH</strong> +17.1%, <strong>SUNW</strong> +8.7%, <strong>VRNT</strong> +7.7%, <strong>OLLI</strong> +2.4%, <strong>UNF</strong> +2.2%, <strong>HOTR</strong> +0.5%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>EXAR</strong> +22.2% (to be acquired by MaxLinear (MXL) for $13.00/share in cash)</li><li><strong>CERU</strong> +17.2% (Pending merger partner Daré Bioscience discloses 20.7% active stake), . </li></ul><p><strong>Other news</strong>:</p><ul><li><strong>TNXP</strong> +51.9% (will present at The MicroCap Conference on April 4)</li><li><strong>CBIO</strong> +30.3% (continued strength following yesterday's 180% move higher)</li><li><strong>SNOA</strong> +19.9% (confirms FDA 510(k) clearance for Loyon Skin Descaler)</li><li><strong>VRTX</strong> +19% (confirms two Phase 3 Studies of the tezacaftor/ivacaftor combination treatment met primary endpoints with statistically significant improvements in lung function in people with cystic fibrosis)</li><li><strong>SGMO</strong> +16% (presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression using the Co's zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology)</li><li><strong>DRWI</strong> +14.8% (DragonWave's Harmony Enhanced MC backhaul solution was selected by Knoxville Utilities Board )</li><li><strong>IDXG</strong> +12.8% (confirms earnings release date for March 29 after the stock market closes)</li><li><strong>ZSAN</strong> +9.4% (Amzak Capital Management disclosed increased passive stake to 13.51% (prior 3.61%))</li><li><strong>DRYS</strong> +8% (continued strength)</li><li><strong>VIAV</strong> +5.1% (AlphaOne Capital Partners' Daniel Niles mention on CNBC FastMoney)</li><li><strong>EGLT</strong> +5% (FDA does not object to Egalet's distribution of promotional materials and communications to healthcare professionals regarding the abuse-deterrent properties of ARYMO ER release tablets)</li><li><strong>LITE</strong> +2.4% (AlphaOne Capital Partners' Daniel Niles mention on CNBC FastMoney )</li><li><strong>WSM</strong> +1% (RH sympathy)</li><li><strong>ACOR</strong> +1% (announces results from two studies of CVT-30g)</li><li><strong>INOV</strong> +1% (enters into an agreement with Amgen (AMGN) focusedspecifically on rheumatoid arthriti)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>CC</strong> +3% (upgraded to Buy from Hold at Jefferies)</li><li><strong>EGO</strong> +2.8% (upgraded to Buy from Hold at Canaccord Genuity)</li><li><strong>NRG</strong> +2.2% (upgraded to Buy from Neutral at Goldman)</li><li><strong>FTNT</strong> +2% (upgraded to Outperform at Robert W. Baird)</li><li><strong>MS</strong> +1.1% (upgraded to Buy from Hold at Deutsche Bank)</li><li><strong>AMZN</strong> +0.5% (initiated with Overweight ratings at Barclays)</li><li><strong>BABA</strong> +0.5% (initiated with Overweight ratings at Barclays)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>QHC</strong> -29.4%, <strong>DCTH</strong> -20.8%, <strong>PTX</strong> -11.1%, <strong>CYCC</strong> -8.5%, <strong>OREX</strong> -6.8%</li><li><strong>DEPO</strong> -4.4%, (announces that Arthur J. Higgins has joined the Co as President and CEO and member of the Board of Directors, following the resignation of James Schoeneck as President and CEO and member of the Board of Directors; guides Q1 net sales of $95-$100 mln)</li><li><strong>IZEA</strong> -3.4%, <strong>SCWX</strong> -3.3%, <strong>PLAY</strong> -3.1%, <strong>SONC</strong> -1.1%, <strong>GLUU</strong> -0.9%, <strong>WLB</strong> -0.8%</li></ul><p><strong>Select EU financial related names showing weakness</strong>:</p><ul><li><strong>PUK</strong> -3.2%, <strong>SAN</strong> -1.6%, <strong>BCS</strong> -1.2%, <strong>CS</strong> -1.1%, <strong>HSBC</strong> -1%, <strong>DB</strong> -1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>ALQA</strong> -36% (prices 9.375 mln common stock offering at $0.40/share)</li><li><strong>ATOS</strong> -29.4% (prices $4 mln public offering consisting of units, common stock and warrants)</li><li><strong>DFFN</strong> -7.2% (following 80%+ move higher following US PTO news) </li><li><strong>AEZS</strong> -5.9% (commences new 'at-the-market' offering of up to 3 mln common shares)</li><li><strong>CARB</strong> -3.8% ( to offer $125 mln aggregate principal amount of Convertible Senior Notes due 2022 in a private offering)</li><li><strong>BPMC</strong> -2.8% (commences underwritten public offering of $150 mln in shares of its common stock)</li><li><strong>HPJ</strong> -2% (following today's notable move higher / close at HoD)</li><li><strong>BAK</strong> -0.9% (extends timeframe to finalize its audited FY16 financial statements)</li><li><strong>ATH</strong> -0.7% (upsizes offering by 2.5 mln shares and prices secondary offering by selling shareholders of 27.5 mln shares of common stock at $48.50), .</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>SKX</strong> -4.9% (downgraded to Negative from Positive at Susquehanna)</li><li><strong>FFIV</strong> -3.1% (downgraded to Sell from Hold at Deutsche Bank)</li><li><strong>DNKN</strong> -2.8% (downgraded to Sell from Neutral at Goldman)</li><li><strong>GRPN</strong> -1.8% (initiated with Underweight ratings at Barclays)</li><li><strong>USG</strong> -1% (downgraded to Neutral from Outperform at Macquarie)</li><li><strong>TWTR</strong> -0.6% (initiated with Underweight ratings at Barclays)</li></ul>"